Cholesteatoma
New cholesteatoma research, summarized each month in plain language.
2026 so far: In January 2026 to September 2026, surgery studies focused on preventing recurrence (especially with obliteration) and on recovery tradeoffs. Imaging studies refined when diffusion-weighted MRI is most useful and how CT+MRI together can improve diagnostic accuracy. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Obliteration and recurrence. Signals strengthened, but reviews stress heterogeneous, non-high-level evidence.
- Endoscopic vs microscope surgery. More head-to-head comparisons reported similar control in selected cases.
- Recovery and function. More attention to patient-impact outcomes beyond disease removal alone.
- MRI follow-up timing. Evidence converged that detection can be delayed, supporting longer surveillance.
- Imaging accuracy and AI. Combined imaging improved confidence; AI ranged from helpful to unreliable.
New
September 2026
- Hearing retesting. Hearing tests after surgery can reveal poor hearing and further options.
- Next-step care. Some people may need repeat surgery, hearing implants, or both.
- Obliteration and recurrence. Obliteration may reduce recurrence, but evidence quality is limited.
August 2026
- CT with diffusion MRI. CT plus diffusion MRI improved confidence in finding cholesteatoma.
- MRI-only follow-up. Some small, symptom-free recurrences were followed with MRI without surgery.
- Endoscopic vs microscope. Reports found similar disease control with endoscopic and microscope surgery.
- General AI CT reading. General-purpose AI did poorly when reading limited CT images alone.
July 2026
- Surgery options. Different operations showed different average hearing changes.
- Short-term recovery. Endoscopic surgery was linked to less pain at one month.
- Hearing risk factors. Longer disease and frequent drainage were linked to worse inner-ear hearing.
- Taste side effects. Keeping the taste nerve was linked to fewer taste changes.
June 2026
- Stapes preservation. Keeping the stapes was linked to better hearing test gains.
- Post-surgery healing. Most reconstructed cavities healed early, but some needed more care.
- CT scan match. High-resolution CT often matched surgery for common bone erosion.
- MRI timing. Models suggested residual disease may take years to show on MRI.
May 2026
- Middle ear healing. Nasal cell sheets may help the ear lining heal after surgery.
- Fistula surgery outcomes. Hearing was often stable after surgery for labyrinthine fistula cases.
- CT scan AI. CT deep-learning models performed well in single-center studies.
- Implant MRI distortion. One bone-conduction implant distorted MRI on the implanted side.
April 2026
- Dual-endoscope surgery. A dual-endoscope approach was linked to faster healing and fewer short-term issues.
- Unplanned second surgery. Unplanned second surgeries were often due to scarring or a shifted hearing prosthesis.
- 6-week complications. Severe complications within 6 weeks were uncommon in a large cohort.
- CT missed thin disease. Thin, sheet-like cholesteatoma could be missed on CT scans.
March 2026
- After-surgery goals. More ears stayed dry, and hearing often improved.
- Later return risk. Retraction pockets or return can show up months to years later.
- MRI follow-up window. Diffusion MRI may help most starting about 12 to 24 months.
- Mental health link. Records linked cholesteatoma codes with more depression diagnoses.
February 2026
- Surgery type. More visible disease often led to a different operation.
- Hearing change. Hearing often improved, with similar short-term results across groups.
- Endoscopic MRI check. In one endoscopic-only group, MRI showed no return at 12 months.
- Inflammation genetics. Genetic signals linked to inflammation, with unclear care impact.
January 2026
- Return risk. Filling the mastoid space was linked to fewer recurrences.
- After-surgery recovery. Many improved after surgery, but some had complications.
- Seeing disease in surgery. Autofluorescence imaging helped identify cholesteatoma during surgery.
- Genetic signals. Early gene studies suggested differences by age and risk.
Get the monthly update by email
Subscribe here to receive an email when a new monthly cholesteatoma update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).